Loading patent…
AssigneeDuke University
InventorsPriya S. Kishnani, Suhrad G. Banugaria, Dwight D. Koeberl, Sean N. Prater
Estimating the term…
The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.
A method for reducing titers of antibodies against a therapeutic protein in a patient treated with the therapeutic protein by administration of a nucleic acid comprising a nucleotide sequence encoding the therapeutic protein in expressible form, said administration able to elicit said antibodies, wherein the therapeutic protein is a proteinaceous replacement for acid alpha-glucosidase (GAA), comprising administering to the patient a proteasome inhibitor in an amount and under conditions that the antibody titers are reduced.
A method for reducing titers of antibodies elicited by administration of a viral vector comprising a nucleotide sequence encoding a therapeutic protein in expressible form in a patient treated with the viral vector comprising administering to the patient a proteasome inhibitor in an amount and under conditions that the antibody titers are reduced.
A method to reduce or prevent the production of antibodies elicited against a therapeutic agent in a patient treated with the therapeutic agent, wherein the therapeutic agent is a viral vector, wherein the viral vector comprises a nucleic acid encoding a therapeutic protein in expressible form, said treatment comprising administration of said therapeutic agent, and said therapeutic agent able to elicit said antibodies, the method comprising administering to the patient, prior to administration of the therapeutic agent, an amount of a proteasome inhibitor sufficient to effect said reduction or prevention.
Dependencies are inferred from the claim text.